BioNTech (NASDAQ:BNTX) Trading 2.7% Higher

Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) rose 2.7% during trading on Monday . The stock traded as high as $88.93 and last traded at $88.85. Approximately 546,858 shares were traded during mid-day trading, a decline of 17% from the average daily volume of 658,333 shares. The stock had previously closed at $86.48.

Analysts Set New Price Targets

BNTX has been the topic of a number of recent analyst reports. HC Wainwright reduced their price objective on BioNTech from $133.00 to $107.00 and set a "buy" rating on the stock in a research note on Tuesday, January 23rd. JPMorgan Chase & Co. lowered their price target on BioNTech from $99.00 to $90.00 and set an "underweight" rating for the company in a report on Friday, March 22nd. UBS Group reduced their price objective on BioNTech from $110.00 to $101.00 and set a "neutral" rating for the company in a research report on Wednesday, March 27th. Canaccord Genuity Group restated a "buy" rating and issued a $171.00 price target on shares of BioNTech in a research note on Thursday, March 21st. Finally, The Goldman Sachs Group reduced their target price on BioNTech from $113.00 to $100.00 and set a "neutral" rating for the company in a research note on Wednesday, February 28th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $120.40.

BioNTech Stock Up 1.6 %

The stock has a 50-day simple moving average of $91.86 and a two-hundred day simple moving average of $97.80. The company has a quick ratio of 9.26, a current ratio of 9.43 and a debt-to-equity ratio of 0.01. The firm has a market cap of $20.89 billion, a PE ratio of 21.33 and a beta of 0.23.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $2.64 by ($0.59). The company had revenue of $1.59 billion for the quarter, compared to the consensus estimate of $2.04 billion. BioNTech had a net margin of 24.26% and a return on equity of 4.60%. Analysts expect that BioNTech SE will post -1.67 earnings per share for the current year.

Institutional Trading of BioNTech

Several large investors have recently modified their holdings of BNTX. GAMMA Investing LLC lifted its holdings in shares of BioNTech by 121.0% during the first quarter. GAMMA Investing LLC now owns 274 shares of the company's stock valued at $25,000 after purchasing an additional 150 shares during the last quarter. CWM LLC grew its position in shares of BioNTech by 657.6% during the 4th quarter. CWM LLC now owns 250 shares of the company's stock valued at $26,000 after acquiring an additional 217 shares during the period. State of Wyoming bought a new stake in shares of BioNTech during the 2nd quarter valued at $26,000. Frazier Financial Advisors LLC bought a new stake in shares of BioNTech during the 4th quarter valued at $30,000. Finally, Covestor Ltd bought a new stake in shares of BioNTech during the 3rd quarter valued at $32,000. 15.52% of the stock is owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.